CSIMarket Company Name, Ticker, Competitors, else..
 
Viridian Therapeutics Inc   (NASDAQ: VRDN)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 
Price: $22.9200 $-0.04 -0.174%
Day's High: $23.030000686645508 Week Perf: -1.04 %
Day's Low: $ 22.62 30 Day Perf: 1.82 %
Volume (M): 759,900 52 Wk High: $ 34.29
Volume (M$): $ 0 52 Wk Avg: $23.50
Open: $22.62 52 Wk Low: $13.18



 Market Capitalization (Millions $) 2,343
 Shares Outstanding (Millions) 102
 Employees 252
 Revenues (TTM) (Millions $) 71
 Net Income (TTM) (Millions $) -371
 Cash Flow (TTM) (Millions $) 77
 Capital Exp. (TTM) (Millions $) 1

Business Description


Viridian Therapeutics Inc is a biotechnology company that focuses on developing treatments for metabolic diseases. The company is known for its expertise in gene therapy and its innovative approach to developing personalized medicines. Viridian Therapeutics aims to address various metabolic diseases, such as obesity and type 2 diabetes, by targeting specific genetic factors and developing targeted therapies. The company takes advantage of advances in genomic research to identify genetic mutations and develop treatments that directly address the underlying causes of metabolic diseases. With a strong emphasis on personalized medicine, Viridian Therapeutics aims to revolutionize the way metabolic diseases are treated by providing tailored therapies that are specifically designed for each patient.


   Company Address: 221 Crescent Street Waltham 2453 MA
   Company Phone Number: 272-4600   Stock Exchange / Ticker: NASDAQ VRDN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
INCY        1.91% 
AMGN        1.11% 
CPRX        0.06% 
EYPT        2.23% 
IMVT   -4.73%    
REGN        4.22% 
• View Complete Report
   



Business Update

Viridian Therapeutics Poised for Impact Amid Mixed Clinical Trial and Revenue Developments

Published Mon, Dec 16 2024 5:42 AM UTC

As December 16, 2024 approaches, all eyes will be on Viridian Therapeutics, Inc. (NASDAQ: VRDN) as the biopharmaceutical company prepares to unveil the topline results from its THRIVE-2 Phase 3 clinical trial evaluating its promising product, veligrotug, for the treatment of chronic Thyroid Eye Disease (TED). This pivotal moment represents a crucial juncture for Viridian, as...
Business Update

Viridian Therapeutics Unveiling the Future of TED Treatment with Phase 3 Veligrotug Trial,

Published Sat, Dec 14 2024 5:53 AM UTC

Viridian Therapeutics to Unveil Phase 3 Results for Promising Treatment of Chronic TED In a highly anticipated announcement, Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company with a concentrated focus on severe and rare diseases, revealed its plans to broadcast the topline results from its Phase 3 THRIVE-2 clinical trial. Throughout the biotech communit...
Business Update

Viridian Therapeutics Delivers Strong Q3 2024 Results and Significantly Improves Financial Metrics,

Published Tue, Nov 12 2024 3:36 PM UTC

WALTHAM, Mass. Viridian Therapeutics, Inc. (NASDAQ: VRDN), a pioneering biotechnology firm dedicated to the discovery and development of innovative medicines for serious and rare diseases, announced its financial results and business progress for the third quarter ending September 30, 2024. The report highlighted significant operational achievements across the company s Th...
Business Update

Viridians Vital Webcast Will VRDN-001 be the Turning Point for Thyroid Eye Disease,

Published Tue, Sep 10 2024 3:20 AM UTC

Viridian Therapeutics Set to Unveil Pivotal Data on VRDN-001 A Game-Changer in Treatment for Thyroid Eye DiseaseWALTHAM, Mass. Viridian Therapeutics, Inc. (NASDAQ: VRDN), a trailblazer in the biopharmaceutical arena, is gearing up to present critical topline data from its THRIVE Phase 3 clinical trial evaluating VRDN-001, a potential best-in-class therapy for patients grappl...
Business Update

Viridian Therapeutics Paves the Way for Innovation with Inducement Grants to Attract Top Talent

Published Wed, Jul 3 2024 12:47 PM UTC

Viridian Therapeutics Induces Grants to Attract Top Talent and Drive InnovationIn a recent press release, Viridian Therapeutics, a leading biopharmaceutical company specializing in the discovery and development of breakthrough medicines for serious and rare diseases, announced its approval of inducement grants under Nasdaq Listing Rule 5635(c)(4). These grants include non-qu...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 33.04
Price to Sales (Expected) -
Price to Book 3.68
PEG (TTM) -

Financial Strength Current
Quick Ratio 11.31
Working Capital Ratio 15.15
Leverage Ratio (MRQ) 0.24
Total Debt to Equity 0.14
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.24 $
Revenues (TTM) 0.69 $
Cash Flow (TTM) 0.75 $
Cash 5.73 $
Book Value 6.22 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 281,365
Net Income per Employee (TTM) -1,471,480
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.1

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -82389.36 %
Net Margin (MRQ) -74397.87 %
Net Cash Flow Margin (MRQ) -25557.45 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Viridian Therapeutics Inc's Segments
License    -4.26 % of total Revenue
Reportable License    4.26 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.